Lupus Research Alliance Applauds U.S. FDA Fast Track Designation for Nipocalimab for Systemic Lupus Erythematosus
Decision Could Help Potential SLE Treatment Reach People Living With Lupus Sooner The Lupus Research Alliance applauds the decision by the U.S. Food and Drug Administration (FDA) to grant Fast Track designation for nipocalimab in development by Johnson & Johnson for the treatment of adults with systemic lupus erythematosus (SLE) – a chronic autoimmune disease for which there are few treatment options. The FDA grants this designation “to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need” – with the goal of … Lupus Research Alliance Applauds U.S. FDA Fast Track Designation for Nipocalimab for Systemic Lupus Erythematosus
